|
1
|
Cools-Lartigue J, Spicer J and Ferri LE:
Current status of management of malignant disease: Current
management of esophageal cancer. J Gastrointest Surg. 19:964–972.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Liu B, Jia Y, Cao Y, Wu S, Jiang H, Sun X,
Ma J, Yin X, Mao A and Shang M: Overexpression of phosphoserine
aminotransferase 1 (PSAT1) predicts poor prognosis and associates
with tumor progression in human esophageal squamous cell carcinoma.
Cell Physiol Biochem. 39:395–406. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Enzinger PC and Mayer RJ: Esophageal
cancer. N Engl J Med. 349:2241–2252. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liu J, Xie X, Zhou C, Peng S, Rao D and Fu
J: Which factors are associated with actual 5 year survival of
oesophageal squamous cell carcinoma? Eur J Cardiothorac Surg.
41:e7–e11. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Toh Y, Egashira A and Yamamoto M:
Epigenetic alterations and their clinical implications in
esophageal squamous cell carcinoma. Gen Thorac Cardiovasc Surg.
61:262–269. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Song Y, Li L, Ou Y, Gao Z, Li E, Li X,
Zhang W, Wang J, Xu L, Zhou Y, et al: Identification of genomic
alterations in oesophageal squamous cell cancer. Nature. 509:91–95.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nature Rev Cancer. 6:857–866. 2006. View Article : Google Scholar
|
|
9
|
Kloosterman WP and Plasterk RH: The
diverse functions of microRNAs in animal development and disease.
Dev Cell. 11:441–450. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rupaimoole R and Slack FJ: MicroRNA
therapeutics: Towards a new era for the management of cancer and
other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Iorio MV and Croce CM: MicroRNA
dysregulation in cancer: Diagnostics, monitoring and therapeutics.
A comprehensive review. EMBO Mol Med. 9:8522017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mei LL, Qiu YT, Zhang B and Shi ZZ:
MicroRNAs in esophageal squamous cell carcinoma: Potential
biomarkers and therapeutic targets. Cancer Biomark. 19:1–9. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Askandar Iqbal M, Arora S, Prakasam G,
Calin GA and Syed MA: MicroRNA in lung cancer: Role, mechanisms,
pathways and therapeutic relevance. Mol Aspects Med.
17:300065–300067. 2018.
|
|
14
|
Yang S, Sun Z, Zhou Q, Wang W, Wang G,
Song J, Li Z, Zhang Z, Chang Y, Xia K, et al: MicroRNAs, long
noncoding RNAs, and circular RNAs: Potential tumor biomarkers and
targets for colorectal cancer. Cancer Manag Res. 10:2249–2257.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yuan HL, Wang T and Zhang KH: MicroRNAs as
potential biomarkers for diagnosis, therapy and prognosis of
gastric cancer. OncoTargets Ther. 11:3891–3900. 2018. View Article : Google Scholar
|
|
16
|
Sharma N and Baruah MM: The microRNA
signatures: Aberrantly expressed miRNAs in prostate cancer. Clin
Transl Oncol. 21:126–144. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li B, Xu WW, Han L, Chan KT, Tsao SW, Lee
NPY, Law S, Xu LY, Li EM, Chan KW, et al: MicroRNA-377 suppresses
initiation and progression of esophageal cancer by inhibiting CD133
and VEGF. Oncogene. 36:3986–4000. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lindner K, Eichelmann AK, Matuszcak C,
Hussey DJ, Haier J and Hummel R: Complex epigenetic regulation of
chemotherapy resistance and biohlogy in esophageal squamous cell
carcinoma via microRNAs. Int J Mol Sci. 19:E4992018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mayne GC, Hussey DJ and Watson DI:
MicroRNAs and esophageal cancer-implications for pathogenesis and
therapy. Curr Pharm Des. 19:1211–1226. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xue L, Nan J, Dong L, Zhang C, Li H, Na R,
He H and Wang Y: Upregulated miR-483-5p expression as a prognostic
biomarker for esophageal squamous cell carcinoma. Cancer Biomark.
19:193–197. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Islam F, Gopalan V, Law S, Tang JC, Chan
KW and Lam AK: MiR-498 in esophageal squamous cell carcinoma:
Clinicopathological impacts and functional interactions. Human
Pathol. 62:141–151. 2017. View Article : Google Scholar
|
|
22
|
Sun X, Dongol S, Qiu C, Xu Y, Sun C, Zhang
Z, Yang X, Zhang Q and Kong B: MiR-652 promotes tumor proliferation
and metastasis by targeting RORA in endometrial cancer. Mol Cancer
Res. 16:1927–1939. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yang W, Zhou C, Luo M, Shi X, Li Y, Sun Z,
Zhou F, Chen Z and He J: MiR-652-3p is upregulated in non-small
cell lung cancer and promotes proliferation and metastasis by
directly targeting Lgl1. Oncotarget. 7:16703–16715. 2016.PubMed/NCBI
|
|
24
|
Jiang Q, Lu X, Huang P, Gao C, Zhao X,
Xing T, Li G, Bao S and Zheng H: Expression of miR-652-3p and
effect on apoptosis and drug sensitivity in pediatric acute
lymphoblastic leukemia. BioMed Res Int. 5:57246862018.
|
|
25
|
Deng S, Li X, Niu Y, Zhu S, Jin Y, Deng S,
Chen J, Liu Y, He C, Yin T, et al: MiR-652 inhibits acidic
microenvironment-induced epithelial-mesenchymal transition of
pancreatic cancer cells by targeting ZEB1. Oncotarget.
6:39661–39675. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sugiura K, Ozawa S, Kitagawa Y, Ueda M and
Kitajima M: Co-expression of aFGF and FGFR-1 is predictive of a
poor prognosis in patients with esophageal squamous cell carcinoma.
Oncol Rep. 17:557–564. 2007.PubMed/NCBI
|
|
28
|
Kim HS, Lee SE, Bae YS, Kim DJ, Lee CG,
Hur J, Chung H, Park JC, Jung DH, Shin SK, et al: Fibroblast growth
factor receptor 1 gene amplification is associated with poor
survival in patients with resected esophageal squamous cell
carcinoma. Oncotarget. 6:2562–2572. 2015.PubMed/NCBI
|
|
29
|
Song Q, Liu Y, Jiang D, Wang H, Huang J,
Xu Y, Sujie A, Zeng H, Xu C and Hou Y: High amplification of FGFR1
gene is a delayed poor prognostic factor in early stage ESCC
patients. Oncotarget. 8:74539–74553. 2017.PubMed/NCBI
|
|
30
|
Wang D, Du L, Wang Z, Liu X, Qin Y, Wang
Q, Yang Z, Yao Z, Shi M, Shang B, et al: Association of fibroblast
growth factor receptor 1 gene amplification with poor survival in
patients with esophageal squamous cell carcinoma. Oncotarget.
8:88857–88869. 2017.PubMed/NCBI
|
|
31
|
Chen B, Liu S, Gan L, Wang J, Hu B, Xu H,
Tong R, Yang H, Cristina I, Xue J, et al: FGFR1 signaling
potentiates tumor growth and predicts poor prognosis in esophageal
squamous cell carcinoma patients. Cancer Biol Ther. 19:76–86. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ma T, Zhao Y, Lu Q, Lu Y, Liu Z, Xue T and
Shao Y: MicroRNA-30c functions as a tumor suppressor via targeting
SNAI1 in esophageal squamous cell carcinoma. Biomed Pharmacothe.
98:680–686. 2018. View Article : Google Scholar
|
|
33
|
Qi B, Wang Y, Chen ZJ, Li XN, Qi Y, Yang
Y, Cui GH, Guo HZ, Li WH and Zhao S: Down-regulation of
miR-30a-3p/5p promotes esophageal squamous cell carcinoma cell
proliferation by activating the Wnt signaling pathway. World J
Gastroenterol. 23:7965–7977. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cui XB, Peng H, Li RR, Mu JQ, Yang L, Li
N, Liu CX, Hu JM, Li SG, Wei Y, et al: MicroRNA-34a functions as a
tumor suppressor by directly targeting oncogenic PLCE1 in Kazakh
esophageal squamous cell carcinoma. Oncotarget. 8:92454–92469.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yang B, Xie R, Wu SN, Gao CC, Yang XZ and
Zhou JF: MicroRNA-615-5p targets insulin-like growth factor 2 and
exerts tumor-suppressing functions in human esophageal squamous
cell carcinoma. Oncol Rep. 39:255–263. 2018.PubMed/NCBI
|
|
36
|
Zuo J, Zhu K, Wang Y and Yu Z:
MicroRNA-34a suppresses invasion and metastatic in esophageal
squamous cell carcinoma by regulating CD44. Mol Cell Biochem.
443:139–149. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gao X, Xie Z, Wang Z, Cheng K, Liang K and
Song Z: Overexpression of miR-191 predicts poor prognosis and
promotes proliferation and invasion in esophageal squamous cell
carcinoma. Yonsei Med J. 58:1101–1110. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Turner CA, Calvo N, Frost DO, Akil H and
Watson SJ: The fibroblast growth factor system is downregulated
following social defeat. Neurosci Lett. 430:147–150. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Schäfer MH, Lingohr P, Sträßer A, Lehnen
NC, Braun M, Perner S, Höller T, Kristiansen G, Kalff JC and
Gütgemann I: Fibroblast growth factor receptor 1 gene amplification
in gastric adenocarcinoma. Human Pathol. 46:1488–1495. 2015.
View Article : Google Scholar
|
|
40
|
Abdul-Maksoud RS, Shalaby SM, Elsayed WS
and Elkady S: Fibroblast growth factor receptor 1 and cytokeratin
20 expressions and their relation to prognostic variables in
bladder cancer. Gene. 591:320–326. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wang K, Ji W, Yu Y, Li Z, Niu X, Xia W and
Lu S: FGFR1-ERK1/2-SOX2 axis promotes cell proliferation,
epithelial-mesenchymal transition, and metastasis in
FGFR1-amplified lung cancer. Oncogene. 27:5340–5354. 2018.
View Article : Google Scholar
|
|
42
|
Cheng CL, Thike AA, Tan SY, Chua PJ, Bay
BH and Tan PH: Expression of FGFR1 is an independent prognostic
factor in triple-negative breast cancer. Breast Cancer Res Treat.
151:99–111. 2015. View Article : Google Scholar : PubMed/NCBI
|
